Chongqing Diabetes Registry Study
CDR
Chongqing Diabetes and Its Chronic Complications Registry Study
1 other identifier
observational
5,000
1 country
1
Brief Summary
To investigate the risk factors and biomarkers of the microvascular disease，macrovascular disease and neuropathy in patients with diabetes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2018
CompletedFirst Submitted
Initial submission to the registry
July 17, 2018
CompletedFirst Posted
Study publicly available on registry
October 2, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2030
September 6, 2023
September 1, 2023
12 years
July 17, 2018
September 4, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The number of patients whoes Diabetic Kidney disease (DKD) is worsen
Worsen DKD is defined as Urine Albumin Creatinine Ratio （UACR）\> 300 mg/g Cr（twice out of three measures）, or 24 hours urinary protein\> 300 mg / 24 h, or double serum creatinine level and at least 200μmol/l (2.26 mg/dl), or require renal replacement therapy, or death due to kidney disease.
5 years
Secondary Outcomes (6)
The number of patients who develop DKD
5 years
The number of patients who develop Diabetic Retinopathy
5 years
The number of patients whoes DR is worsen
5 years
The number of patients who develop Diabetic Neuropathy
5 years
The number of patients who develop Cardiovascular events
10 years
- +1 more secondary outcomes
Eligibility Criteria
The subjects who diagnosed of diabetes mellitus and signed on the informed consent will be enrolled in our study. We intend to enroll hospitalized patients or outpatient with diabetes mellitus from Chongqing Diabetes Centre,Chongqing,China.
You may qualify if:
- Diagnosis of diabetes mellitus（based on the 1999 WHO diagnostic cretirial）;
- Age younger than 75 years old, gender is not limited;
- Voluntary to sign on the informed consent.
You may not qualify if:
- pregnant or breast-feeding women;
- Patients with chronic disease requiring long-term glucocorticoid therapy;
- Patients with severe infection (except for diabetic foot) or immune dysfunction.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Qifu Li
Chongqing, Chongqing Municipality, 400016, China
Related Publications (1)
Lv L, Zhou Y, Chen X, Gong L, Wu J, Luo W, Shen Y, Han S, Hu J, Wang Y, Li Q, Wang Z; Chongqing Diabetes Registry Group. Relationship Between the TyG Index and Diabetic Kidney Disease in Patients with Type-2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2021 Jul 17;14:3299-3306. doi: 10.2147/DMSO.S318255. eCollection 2021.
PMID: 34305401DERIVED
Biospecimen
Serum, plasma,complete blood cell and urine
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Qifu Li, phD
First Affiliated Hospital of Chongqing Medical University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of endocrinology
Study Record Dates
First Submitted
July 17, 2018
First Posted
October 2, 2018
Study Start
July 1, 2018
Primary Completion (Estimated)
July 1, 2030
Study Completion (Estimated)
July 1, 2030
Last Updated
September 6, 2023
Record last verified: 2023-09